Andreas Argyrides
Stock Analyst at Oppenheimer
(4.30)
# 373
Out of 5,156 analysts
122
Total ratings
50.94%
Success rate
17.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOSS Gossamer Bio | Maintains: Outperform | $12 → $3 | $0.56 | +440.25% | 9 | Mar 5, 2026 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $529.17 | +13.39% | 2 | Feb 26, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $30 → $35 | $18.32 | +91.05% | 15 | Feb 24, 2026 | |
| EVMN Evommune | Initiates: Outperform | $42 | $24.61 | +70.66% | 1 | Jan 22, 2026 | |
| DYN Dyne Therapeutics | Upgrades: Outperform | $11 → $40 | $17.69 | +126.12% | 5 | Dec 10, 2025 | |
| SVRA Savara | Maintains: Outperform | $8 → $9 | $5.43 | +65.75% | 2 | Nov 14, 2025 | |
| KROS Keros Therapeutics | Reiterates: Outperform | $23 → $27 | $11.35 | +137.89% | 9 | Nov 12, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Outperform | $77 → $115 | $58.07 | +98.04% | 2 | Oct 2, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $26 → $21 | $5.69 | +269.07% | 2 | Oct 2, 2025 | |
| BNTC Benitec Biopharma | Maintains: Outperform | $35 → $29 | $12.55 | +131.08% | 2 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $33 | $0.26 | +12,567.95% | 2 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $2.68 | +459.70% | 2 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $20 | $5.16 | +287.60% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $61 | $28.57 | +113.51% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 → $7 | $4.29 | +63.17% | 5 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $3 | $0.95 | +215.39% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $13 | $35.87 | -63.76% | 7 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $4 | $1.38 | +189.86% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $155 → $90 | $12.30 | +631.71% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $9 | $1.89 | +376.19% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $239.92 | -24.56% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $9.05 | +109.94% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $27.37 | +5.96% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $10.38 | +102.31% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $17.64 | +1,169.84% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $22.24 | +156.29% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $1.25 | +460.00% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.41 | +2,337.84% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $60.88 | +14.98% | 6 | Aug 1, 2023 |
Gossamer Bio
Mar 5, 2026
Maintains: Outperform
Price Target: $12 → $3
Current: $0.56
Upside: +440.25%
United Therapeutics
Feb 26, 2026
Maintains: Outperform
Price Target: $575 → $600
Current: $529.17
Upside: +13.39%
MoonLake Immunotherapeutics
Feb 24, 2026
Maintains: Outperform
Price Target: $30 → $35
Current: $18.32
Upside: +91.05%
Evommune
Jan 22, 2026
Initiates: Outperform
Price Target: $42
Current: $24.61
Upside: +70.66%
Dyne Therapeutics
Dec 10, 2025
Upgrades: Outperform
Price Target: $11 → $40
Current: $17.69
Upside: +126.12%
Savara
Nov 14, 2025
Maintains: Outperform
Price Target: $8 → $9
Current: $5.43
Upside: +65.75%
Keros Therapeutics
Nov 12, 2025
Reiterates: Outperform
Price Target: $23 → $27
Current: $11.35
Upside: +137.89%
Monopar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $77 → $115
Current: $58.07
Upside: +98.04%
Larimar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $26 → $21
Current: $5.69
Upside: +269.07%
Benitec Biopharma
Sep 16, 2025
Maintains: Outperform
Price Target: $35 → $29
Current: $12.55
Upside: +131.08%
Sep 11, 2025
Maintains: Outperform
Price Target: $15 → $33
Current: $0.26
Upside: +12,567.95%
Sep 5, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $2.68
Upside: +459.70%
Aug 15, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $5.16
Upside: +287.60%
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $28.57
Upside: +113.51%
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $4.29
Upside: +63.17%
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $0.95
Upside: +215.39%
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $35.87
Upside: -63.76%
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $1.38
Upside: +189.86%
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $12.30
Upside: +631.71%
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $1.89
Upside: +376.19%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $239.92
Upside: -24.56%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $9.05
Upside: +109.94%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $27.37
Upside: +5.96%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $10.38
Upside: +102.31%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $17.64
Upside: +1,169.84%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $22.24
Upside: +156.29%
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $1.25
Upside: +460.00%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.41
Upside: +2,337.84%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $60.88
Upside: +14.98%